Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 8864 entries
Sorted by: Best Match Show Resources per page
Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review.

Cancers

Dohmen AJ, Swartz JE, Van Den Brekel MW, Willems SM, Spijker R, Neefjes J, Zuur CL.
PMID: 26343729
Cancers (Basel). 2015 Aug 28;7(3):1716-42. doi: 10.3390/cancers7030858.

Primary human tumor culture models allow for individualized drug sensitivity testing and are therefore a promising technique to achieve personalized treatment for cancer patients. This would especially be of interest for patients with advanced stage head and neck cancer....

Cite
Dohmen AJ, Swartz JE, Van Den Brekel MW, et al. Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review. Cancers (Basel). 2015;7(3):1716-42doi: 10.3390/cancers7030858.
Dohmen, A. J., Swartz, J. E., Van Den Brekel, M. W., Willems, S. M., Spijker, R., Neefjes, J., & Zuur, C. L. (2015). Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review. Cancers, 7(3), 1716-42. https://doi.org/10.3390/cancers7030858
Dohmen, Amy J C, et al. "Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review." Cancers vol. 7,3 (2015): 1716-42. doi: https://doi.org/10.3390/cancers7030858
Dohmen AJ, Swartz JE, Van Den Brekel MW, Willems SM, Spijker R, Neefjes J, Zuur CL. Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review. Cancers (Basel). 2015 Aug 28;7(3):1716-42. doi: 10.3390/cancers7030858. PMID: 26343729; PMCID: PMC4586791.
Copy Download .nbib Format: NLM
New platinum(II) complexes with benzo-thia-zole ligands.

Acta crystallographica. Section E, Crystallographic communications

Carmona-Negrón JA, Cádiz ME, Moore CE, Rheingold AL, Meléndez E.
PMID: 27006819
Acta Crystallogr E Crystallogr Commun. 2016 Feb 24;72:412-6. doi: 10.1107/S2056989016002826. eCollection 2016 Mar 01.

Four new platinum(II) complexes, namely tetra-ethyl-ammonium tri-bromido-(2-methyl-1,3-benzo-thia-zole-κN)platinate(II), [NEt4][PtBr3(C8H7NS)] (1), tetra-ethyl-ammonium tri-bromido-(6-meth-oxy-2-methyl-1,3-benzo-thia-zole-κN)platinate(II), [NEt4][PtBr3(C9H9NOS)] (2), tetra-ethyl-ammonium tri-bromido-(2,5,6-trimethyl-1,3-benzo-thia-zole-κN)platinate(II), [NEt4][PtBr3(C10H11NS)] (3), and tetra-ethyl-ammonium tri-bromido-(2-methyl-5-nitro-1,3-benzo-thia-zole-κN)platinate(II), [NEt4][PtBr3(C8H6N2O2S)] (4), have been synthesized and structurally characterized by single-crystal X-ray diffraction techniques. These species are precursors of compounds...

Cite
Carmona-Negrón JA, Cádiz ME, Moore CE, et al. New platinum(II) complexes with benzo-thia-zole ligands. Acta Crystallogr E Crystallogr Commun. 2016;72:412-6doi: 10.1107/S2056989016002826.
Carmona-Negrón, J. A., Cádiz, M. E., Moore, C. E., Rheingold, A. L., & Meléndez, E. (2016). New platinum(II) complexes with benzo-thia-zole ligands. Acta crystallographica. Section E, Crystallographic communications, 72412-6. https://doi.org/10.1107/S2056989016002826
Carmona-Negrón, José A, et al. "New platinum(II) complexes with benzo-thia-zole ligands." Acta crystallographica. Section E, Crystallographic communications vol. 72 (2016): 412-6. doi: https://doi.org/10.1107/S2056989016002826
Carmona-Negrón JA, Cádiz ME, Moore CE, Rheingold AL, Meléndez E. New platinum(II) complexes with benzo-thia-zole ligands. Acta Crystallogr E Crystallogr Commun. 2016 Feb 24;72:412-6. doi: 10.1107/S2056989016002826. eCollection 2016 Mar 01. PMID: 27006819; PMCID: PMC4778805.
Copy Download .nbib Format: NLM
Diagnosis and management of patients with malignant peritoneal mesothelioma.

Journal of gastrointestinal oncology

Alexander HR, Burke AP.
PMID: 26941986
J Gastrointest Oncol. 2016 Feb;7(1):79-86. doi: 10.3978/j.issn.2078-6891.2015.134.

Malignant peritoneal mesothelioma (MPM) is a rare neoplastic condition that arises, usually diffusely, from the serosal membranes of the abdominal cavity. MPM represents about 7% to 10% of all mesothelioma diagnoses and this translates into approximately 800 cases per...

Cite
Alexander HR, Burke AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016;7(1):79-86doi: 10.3978/j.issn.2078-6891.2015.134.
Alexander, H. R., & Burke, A. P. (2016). Diagnosis and management of patients with malignant peritoneal mesothelioma. Journal of gastrointestinal oncology, 7(1), 79-86. https://doi.org/10.3978/j.issn.2078-6891.2015.134
Alexander, H Richard, and Burke, Allen P. "Diagnosis and management of patients with malignant peritoneal mesothelioma." Journal of gastrointestinal oncology vol. 7,1 (2016): 79-86. doi: https://doi.org/10.3978/j.issn.2078-6891.2015.134
Alexander HR, Burke AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016 Feb;7(1):79-86. doi: 10.3978/j.issn.2078-6891.2015.134. PMID: 26941986; PMCID: PMC4754312.
Copy Download .nbib Format: NLM
Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.

Oncotarget

Pfankuchen DB, Baltes F, Batool T, Li JP, Schlesinger M, Bendas G.
PMID: 28978053
Oncotarget. 2017 Jun 28;8(40):67553-67566. doi: 10.18632/oncotarget.18738. eCollection 2017 Sep 15.

Low molecular weight heparin (LMWH), the guideline based drug for prophylaxis and treatment of cancer-associated thrombosis, was recently shown to sensitize cisplatin resistant A2780cis human ovarian cancer cells for cisplatin cytotoxicity upon 24 h pretreatment with 50 μg ×...

Cite
Pfankuchen DB, Baltes F, Batool T, et al. Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway. Oncotarget. 2017;8(40):67553-67566doi: 10.18632/oncotarget.18738.
Pfankuchen, D. B., Baltes, F., Batool, T., Li, J. P., Schlesinger, M., & Bendas, G. (2017). Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway. Oncotarget, 8(40), 67553-67566. https://doi.org/10.18632/oncotarget.18738
Pfankuchen, Daniel Bastian, et al. "Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway." Oncotarget vol. 8,40 (2017): 67553-67566. doi: https://doi.org/10.18632/oncotarget.18738
Pfankuchen DB, Baltes F, Batool T, Li JP, Schlesinger M, Bendas G. Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway. Oncotarget. 2017 Jun 28;8(40):67553-67566. doi: 10.18632/oncotarget.18738. eCollection 2017 Sep 15. PMID: 28978053; PMCID: PMC5620193.
Copy Download .nbib Format: NLM
Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study.

Annals of translational medicine

Rattan R, Kapoor R, Bahl A, Gupta R, Oinam AS, Kaur S.
PMID: 27004217
Ann Transl Med. 2016 Feb;4(4):70. doi: 10.3978/j.issn.2305-5839.2016.01.37.

BACKGROUND: Chemoradiation (CRT) is the standard of care in anal canal carcinoma. CRT leads to suppression of iliac bone marrow (BM) leading to hematological toxicity. Intensity modulated radiation therapy (IMRT) technique can be used to decrease radiation dose to...

Cite
Rattan R, Kapoor R, Bahl A, et al. Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. Ann Transl Med. 2016;4(4):70doi: 10.3978/j.issn.2305-5839.2016.01.37.
Rattan, R., Kapoor, R., Bahl, A., Gupta, R., Oinam, A. S., & Kaur, S. (2016). Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. Annals of translational medicine, 4(4), 70. https://doi.org/10.3978/j.issn.2305-5839.2016.01.37
Rattan, Rajit, et al. "Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study." Annals of translational medicine vol. 4,4 (2016): 70. doi: https://doi.org/10.3978/j.issn.2305-5839.2016.01.37
Rattan R, Kapoor R, Bahl A, Gupta R, Oinam AS, Kaur S. Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. Ann Transl Med. 2016 Feb;4(4):70. doi: 10.3978/j.issn.2305-5839.2016.01.37. PMID: 27004217; PMCID: PMC4779784.
Copy Download .nbib Format: NLM
FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties.

American journal of translational research

Wang J, Liu Z, Zhang D, Liu R, Lin Q, Liu J, Yang Z, Ma Q, Sun D, Zhou X, Jiang G.
PMID: 28861158
Am J Transl Res. 2017 Aug 15;9(8):3676-3686. eCollection 2017.

Failure of cancer treatment caused by drug resistance and metastasis is mainly due to existence of cancer stem cells (CSCs). Therefore, targeting CSCs to overcome cancers is a challenging issue in clinic. In this report, in view of the...

Cite
Wang J, Liu Z, Zhang D, et al. FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties. Am J Transl Res. 2017;9(8):3676-3686
Wang, J., Liu, Z., Zhang, D., Liu, R., Lin, Q., Liu, J., Yang, Z., Ma, Q., Sun, D., Zhou, X., & Jiang, G. (2017). FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties. American journal of translational research, 9(8), 3676-3686.
Wang, Jin, et al. "FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties." American journal of translational research vol. 9,8 (2017): 3676-3686.
Wang J, Liu Z, Zhang D, Liu R, Lin Q, Liu J, Yang Z, Ma Q, Sun D, Zhou X, Jiang G. FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties. Am J Transl Res. 2017 Aug 15;9(8):3676-3686. eCollection 2017. PMID: 28861158; PMCID: PMC5575181.
Copy Download .nbib Format: NLM
Membrane-disrupting iridium(iii) oligocationic organometallopeptides.

Chemical communications (Cambridge, England)

Salvadó I, Gamba I, Montenegro J, Martínez-Costas J, Brea JM, Loza MI, Vázquez López M, Vázquez ME.
PMID: 27538788
Chem Commun (Camb). 2016 Sep 21;52(73):11008-11. doi: 10.1039/c6cc05537k. Epub 2016 Aug 19.

A series of oligoarginine peptide derivatives containing cyclometallated iridium(iii) units display remarkable cytotoxicity, comparable to that of cisplatin. In vitro studies with unilamellar vesicles support a membrane-disrupting mechanism of action.

Cite
Salvadó I, Gamba I, Montenegro J, et al. Membrane-disrupting iridium(iii) oligocationic organometallopeptides. Chem Commun (Camb). 2016;52(73):11008-11doi: 10.1039/c6cc05537k.
Salvadó, I., Gamba, I., Montenegro, J., Martínez-Costas, J., Brea, J. M., Loza, M. I., Vázquez López, M., & Vázquez, M. E. (2016). Membrane-disrupting iridium(iii) oligocationic organometallopeptides. Chemical communications (Cambridge, England), 52(73), 11008-11. https://doi.org/10.1039/c6cc05537k
Salvadó, Iria, et al. "Membrane-disrupting iridium(iii) oligocationic organometallopeptides." Chemical communications (Cambridge, England) vol. 52,73 (2016): 11008-11. doi: https://doi.org/10.1039/c6cc05537k
Salvadó I, Gamba I, Montenegro J, Martínez-Costas J, Brea JM, Loza MI, Vázquez López M, Vázquez ME. Membrane-disrupting iridium(iii) oligocationic organometallopeptides. Chem Commun (Camb). 2016 Sep 21;52(73):11008-11. doi: 10.1039/c6cc05537k. Epub 2016 Aug 19. PMID: 27538788.
Copy Download .nbib Format: NLM
Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin.

Nanoscale research letters

Kutwin M, Sawosz E, Jaworski S, Kurantowicz N, Strojny B, Chwalibog A.
PMID: 25114629
Nanoscale Res Lett. 2014 May 23;9(1):257. doi: 10.1186/1556-276X-9-257. eCollection 2014.

Side effects and resistance of cancer cells to cisplatin are major drawbacks to its application, and recently, the possibility of replacing cisplatin with nanocompounds has been considered. Most chemotherapeutic agents are administered intravenously, and comparisons between the interactions of...

Cite
Kutwin M, Sawosz E, Jaworski S, et al. Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin. Nanoscale Res Lett. 2014;9(1):257doi: 10.1186/1556-276X-9-257.
Kutwin, M., Sawosz, E., Jaworski, S., Kurantowicz, N., Strojny, B., & Chwalibog, A. (2014). Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin. Nanoscale research letters, 9(1), 257. https://doi.org/10.1186/1556-276X-9-257
Kutwin, Marta, et al. "Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin." Nanoscale research letters vol. 9,1 (2014): 257. doi: https://doi.org/10.1186/1556-276X-9-257
Kutwin M, Sawosz E, Jaworski S, Kurantowicz N, Strojny B, Chwalibog A. Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin. Nanoscale Res Lett. 2014 May 23;9(1):257. doi: 10.1186/1556-276X-9-257. eCollection 2014. PMID: 25114629; PMCID: PMC4113027.
Copy Download .nbib Format: NLM
Curcumin Ameliorates Functional and Structural Abnormalities in Cisplatin-induced Neuropathy.

Experimental neurobiology

Agthong S, Kaewsema A, Charoensub T.
PMID: 26113793
Exp Neurobiol. 2015 Jun;24(2):139-45. doi: 10.5607/en.2015.24.2.139. Epub 2015 Apr 27.

Peripheral neuropathy is one of the major side effects of cisplatin; however, effective treatments are lacking. Curcumin is a polyphenol found in the root of Curcuma longa and has been shown neuroprotective against several neurological diseases. Nevertheless, its effects...

Cite
Agthong S, Kaewsema A, Charoensub T. Curcumin Ameliorates Functional and Structural Abnormalities in Cisplatin-induced Neuropathy. Exp Neurobiol. 2015;24(2):139-45doi: 10.5607/en.2015.24.2.139.
Agthong, S., Kaewsema, A., & Charoensub, T. (2015). Curcumin Ameliorates Functional and Structural Abnormalities in Cisplatin-induced Neuropathy. Experimental neurobiology, 24(2), 139-45. https://doi.org/10.5607/en.2015.24.2.139
Agthong, Sithiporn, et al. "Curcumin Ameliorates Functional and Structural Abnormalities in Cisplatin-induced Neuropathy." Experimental neurobiology vol. 24,2 (2015): 139-45. doi: https://doi.org/10.5607/en.2015.24.2.139
Agthong S, Kaewsema A, Charoensub T. Curcumin Ameliorates Functional and Structural Abnormalities in Cisplatin-induced Neuropathy. Exp Neurobiol. 2015 Jun;24(2):139-45. doi: 10.5607/en.2015.24.2.139. Epub 2015 Apr 27. PMID: 26113793; PMCID: PMC4479810.
Copy Download .nbib Format: NLM
Bleomycin-induced flagellate erythema: A case report and review of the literature.

Oncology letters

Lee HY, Lim KH, Ryu Y, Song SY.
PMID: 25009666
Oncol Lett. 2014 Aug;8(2):933-935. doi: 10.3892/ol.2014.2179. Epub 2014 May 26.

Bleomycin has been used most commonly in the treatment of Hodgkin's lymphoma, certain germ cell tumors (GCT) and for the sclerosis of recurrent pleural effusions. Bleomycin toxicity predominantly affects the skin and lungs. Skin toxicity includes Raynaud's phenomenon, hyperkeratosis,...

Cite
Lee HY, Lim KH, Ryu Y, et al. Bleomycin-induced flagellate erythema: A case report and review of the literature. Oncol Lett. 2014;8(2):933-935doi: 10.3892/ol.2014.2179.
Lee, H. Y., Lim, K. H., Ryu, Y., & Song, S. Y. (2014). Bleomycin-induced flagellate erythema: A case report and review of the literature. Oncology letters, 8(2), 933-935. https://doi.org/10.3892/ol.2014.2179
Lee, Hui-Young, et al. "Bleomycin-induced flagellate erythema: A case report and review of the literature." Oncology letters vol. 8,2 (2014): 933-935. doi: https://doi.org/10.3892/ol.2014.2179
Lee HY, Lim KH, Ryu Y, Song SY. Bleomycin-induced flagellate erythema: A case report and review of the literature. Oncol Lett. 2014 Aug;8(2):933-935. doi: 10.3892/ol.2014.2179. Epub 2014 May 26. PMID: 25009666; PMCID: PMC4081419.
Copy Download .nbib Format: NLM
Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma.

Molecular and clinical oncology

Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y.
PMID: 26137283
Mol Clin Oncol. 2015 May;3(3):655-662. doi: 10.3892/mco.2015.523. Epub 2015 Mar 03.

The aim of the present study was to predict the effects of transarterial infusion (TAI) chemotherapy based on early changes in α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) in patients with advanced hepatocellular carcinoma (HCC). Seventy-four patients who underwent TAI...

Cite
Oyama K, Koda M, Sugihara T, et al. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol. 2015;3(3):655-662doi: 10.3892/mco.2015.523.
Oyama, K., Koda, M., Sugihara, T., Kishina, M., Miyoshi, K., Okamoto, T., Hodotsuka, M., Fujise, Y., Matono, T., Tokunaga, S., Okamoto, K., Hosho, K., Okano, J., & Murawaki, Y. (2015). Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Molecular and clinical oncology, 3(3), 655-662. https://doi.org/10.3892/mco.2015.523
Oyama, Kenji, et al. "Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma." Molecular and clinical oncology vol. 3,3 (2015): 655-662. doi: https://doi.org/10.3892/mco.2015.523
Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol. 2015 May;3(3):655-662. doi: 10.3892/mco.2015.523. Epub 2015 Mar 03. PMID: 26137283; PMCID: PMC4471610.
Copy Download .nbib Format: NLM
Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells.

Oncology letters

Konac E, Varol N, Kiliccioglu I, Bilen CY.
PMID: 26171069
Oncol Lett. 2015 Jul;10(1):560-564. doi: 10.3892/ol.2015.3250. Epub 2015 May 20.

The proteasome inhibitor bortezomib is a promising novel agent in bladder cancer therapy; however, inducible cytoprotective mechanisms may limit its potential efficacy. To date, the cellular and molecular effects of proteasome inhibitors on bladder cancer cells have been poorly...

Cite
Konac E, Varol N, Kiliccioglu I, et al. Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. Oncol Lett. 2015;10(1):560-564doi: 10.3892/ol.2015.3250.
Konac, E., Varol, N., Kiliccioglu, I., & Bilen, C. Y. (2015). Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. Oncology letters, 10(1), 560-564. https://doi.org/10.3892/ol.2015.3250
Konac, Ece, et al. "Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells." Oncology letters vol. 10,1 (2015): 560-564. doi: https://doi.org/10.3892/ol.2015.3250
Konac E, Varol N, Kiliccioglu I, Bilen CY. Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. Oncol Lett. 2015 Jul;10(1):560-564. doi: 10.3892/ol.2015.3250. Epub 2015 May 20. PMID: 26171069; PMCID: PMC4487089.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 8864 entries